NCT03431350 2025-12-23QUESTJanssen Research & Development, LLCPhase 2 Active not recruiting136 enrolled 29 charts
NCT03248570 2024-11-20Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsUniversity of California, San FranciscoPhase 2 Completed26 enrolled 18 charts